Inclusion Criteria:

- Part A- Diagnosed with advanced and/or metastatic cancer during dose escalation

- Part B- Diagnosed with adenocarcinoma of the colon or rectum, head and neck squamous
cell carcinoma, or cholangiocarcinoma

- Must be at least 18 years of age

- Adequate hematologic, renal, and liver functions

- Eastern Cooperative Oncology Group (ECOG) status of 0 or 1

- Ability to swallow capsules, with the exception of head and neck squamous cell
carcinoma participants who may have study drug crushed and administered through a
feeding tube

Exclusion Criteria:

- Have serious preexisting medical conditions that would preclude participation in the
study

- Have a chronic underlying infection

- Have symptomatic central nervous system (CNS) malignancy or metastasis

- Have current acute or chronic leukemia

- Are pregnant or lactating

- Have hepatocellular cancer, liver cirrhosis with a Child-Pugh stage of B or higher,
or have received a liver transplant

- Have a history of congestive heart failure with a New York Heart Association class
greater than 2, unstable angina, recent myocardial infarction (within 6 months of
study enrollment), transient ischemic attacks, stroke, or arterial or venous vascular
disease

- Have a QTc interval greater than 470 msec

- For participants in Part B, a tumor tissue sample is mandatory for biomarker analysis